Thyroid News

CHICAGO — Radiofrequency ablation remains a safe and viable treatment option for certain patients with thyroid cancer, according to a presenter at the Annual Meeting of the American Thyroid Association.

CHICAGO — Redifferentiation therapy with MEK inhibitor and/or BRAF inhibitor therapy resensitized some patients with metastatic radioactive iodine-refractory thyroid cancer to radioactive iodine, according to retrospective study results presented at the Annual Meeting of the American Thyroid Association.

CHICAGO — Apatinib demonstrated encouraging clinical activity among Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer, according to results of a small phase 2 study presented at the Annual Meeting of the American Thyroid Association.

CHICAGO — In this video exclusive, Endocrine Today Editorial Board Member Stephanie L. Lee, MD, PhD, FACE, ECNU, professor of medicine and director of thyroid health in the section of endocrinology, diabetes and nutrition at Boston Medical Center, discusses four important studies presented at the American Thyroid Association Annual Meeting.

CHICAGO — Thyroid eye disease, a condition most commonly associated with Graves’ hypothyroidism, typically comes with a range of symptoms that can make everyday tasks challenging and quickly reduce quality of life. Within 18 months of a diagnosis of Graves’ disease, approximately 80% of patients will develop thyroid eye disease, with symptoms including proptosis, the main cause or morbidity, as well as eyelid retraction, strabismus and compressive optic neuropathy.

CHICAGO — Research is the backbone of the medical field. Through research, breakthroughs are made to discover how and why diseases develop and how to treat these conditions. For Sissy M. Jhiang, PhD, a professor in the department of physiology and cell biology at The Ohio State University College of Medicine, her work on thyroid cancer research has helped push the field forward, particularly in terms of genetics, thyroid tumor development and radioiodine therapy.

CHICAGO — The American Thyroid Association’s annual Van Meter Award, presented to an investigator younger than 45 years who has made outstanding contributions to thyroid research, was conferred on a cancer epidemiologist for her work elucidating the contributions of environment and lifestyle, particularly obesity, to the rising incidence of thyroid cancer. The 2019 recipient, kept secret until the award lecture at the annual meeting, is Cari Kitahara, PhD, an investigator in the Division of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, of NIH’s National Cancer Institute (NCI).

CHICAGO — Looking for a surgeon who specializes in thyroid nodules, hyperparathyroidism and adrenal masses using the internal search engines offered by hospitals may not be effective, according to findings presented at the annual meeting of the American Thyroid Association.

CHICAGO — Levothyroxine is prescribed to more than 80% of patients despite a lack of supporting evidence from thyroid function laboratory assessments, according to findings presented at the annual meeting of the American Thyroid Association.

Older adults with subclinical hypothyroidism treated with levothyroxine did not experience an improvement in symptoms or quality of life measures compared with similar adults assigned placebo, , according to findings published in JAMA.